Accelerated access review: final report

Department of Health, October 2016

This report sets out recommendations on how patients could get quicker access to innovative new diagnostic tools, treatments, and medical technologies. It argues that streamlined processes could bring forward patient access to drugs by up to four years and patients will benefit from quicker access to medical technologies too. The report will help the NHS to provide the best care to patients, use funds more effectively, and create the conditions to help the life sciences industry continue to thrive.

Click here to view the report.

Multimorbidity: clinical assessment and management. NICE Guideline.

NICE, September 2016

This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

Click here to access the guideline.

Care and treatment reviews to become ‘business as usual’

NHS England, August 2015

NHS England has set out how it intends that reviews of care and treatment arrangements for people with learning disabilities are to be embedded across the health and care system.

Care and Treatment Reviews (CTRs) were developed as part of NHS England’s commitment to improving the care of people with learning disabilities or autism. They aim to reduce unnecessary admissions and lengthy stays in specialist hospitals, and have been rolling out since October 2014; over 1,400 people had their care reviewed up to March this year, with hundreds more since.

Click here to view the full story.

Care and Treatment Review: Policy and Guidance

NHS England, August 2015

This guidance has been produced by building on the learning from the Care and Treatment reviews which have taken place so far, including extensive engagement with people with learning disabilities, their representatives and their families.

The document will help local Clinical Commissioning Groups and NHS England commissioners implement the recommendation from this learning that CTRs should become ‘business as usual’.

Click here to view the full text guidance.

How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease

BMJ, 17 August 2015

Although biologic disease modifying anti-rheumatic drugs (bDMARDs) have improved the quality of life of patients with rheumatoid arthritis, side effects remain a problem, especially for patients with pre-existing comorbidities. Randomized controlled trials of such drugs in rheumatoid arthritis typically exclude patients with comorbidities and are of short duration, so they do not provide data on adverse events in these people. Other data sources such as national bDMARD registries are limited by the preselection of patients for both conventional synthetic chemical compound disease modifying anti-rheumatic drugs (csDMARDs) and bDMARDs, and although these databases document comorbidity, they rarely report its severity. This too limits definitive statements on the progression or resolution of pre-existing disease. Although bDMARDs may not be contraindicated in patients with rheumatoid arthritis and certain comorbid diseases, additional assessments or precautions are recommended. This review summarizes current data on the use of bDMARDs in people with rheumatoid arthritis and common comorbid diseases. It provides an evidence base for doctors and their patients when discussing and selecting the appropriate bDMARDs.

Click here to view the full text paper.  You will need to login with your Athens password to view this article.

All LCFT staff and students are eligible to register for an Athens password. Click here to register or contact the Library.

Practice Pointer – Body Dysmorphic Disorder

BMJ, 18 June 2015

This practice pointer from the BMJ on Body Dysmorphic Disorder provides an overview of the condition, the impact the condition has on patients and treatment options.

Click here to view the full text article.  You will need to login with your Athens account to view this article.

All LCFT staff and students are eligible to register for an Athens account.  Please click here to register for an Athens account.